MedTrace Logo

Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS

NCT04138758 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 42953

Last updated 2021-11-15

Study results available
· View outcomes & findings →

Summary

The primary objective is to compare the effectiveness of maintenance therapy initiation with the combination treatment Tiotropium and Olodaterol (Olo+Tio) compared with LABA/ICS combination in COPD as the time to the first COPD exacerbation.

Secondary objectives are to compare patients treated with Tio+Olo and patients treated with LABA/ ICS combination.

Conditions

Interventions

DRUG

Tiotropium bromide + Olodaterol

Tiotropium bromide + Olodaterol

DRUG

LABA/ICS

Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)

Sponsors & Collaborators

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-01
Primary Completion
2019-11-04
Completion
2019-11-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04138758 on ClinicalTrials.gov